Chai Discovery, an artificial intelligence biology startup founded six months ago, has raised nearly $30 million from heavyweights Thrive Capital and OpenAI to bring AI to drug discovery.
Chai develops AI foundation models that can predict the structure of biochemical molecules and reprogram how they interact, a process that is central to developing new medications. “We want to turn biology from a science into engineering,” said co-founder and Chief Executive Officer Joshua Meier.
Read the full article here